摘要:
The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-&bgr;-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.
摘要:
Labelled nucleotide analogs comprising protein shields for improving enzyme photostability in single molecule real time sequencing. Nucleotide analogs of the invention have a protein shield based on bis-biotin and avidin between the dye moieties and nucleotide moieties of the analog. The protein prevents the direct interaction of the dye moiety with the enzyme carrying out nucleotide synthesis preventing photodamage to the enzyme. The nucleotide analogs of the invention can have multiple dyes and multiple nucleotide moieties.
摘要:
This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.
摘要:
Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
摘要:
Disclosed herein is a process for preparing an enantiomerically- or a diastereomerically enriched phosphorus-containing active, salt, or pharmaceutically acceptable salt thereof, of formula I-1
, which comprises the steps of: (a) reacting a protected or unprotected Active with a base to form a salt of said active and then reacting said salt with an enantiomerically- or a diastereomerically enriched compound of formula II-1
wherein the Active is a nucleoside, a nucleoside-analog, or a non-nucleoside.
摘要:
The present invention provides (i) processes for preparing a 2'-deoxy-2'fluoro-2'-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2'-deoxy-2'-fluoro-2'-C-methyl-ss-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
摘要:
The present invention relates to a compound represented by formula (I)
wherein X is selected from the group of formulae (II) to (IV)
wherein R 1 is H or C 1 -C 50 chain which may be branched or linear and which may be saturated or unsaturated and which may optionally be interrupted and/or substituted by one or more hetero atom(s) (Het1) and/or functional group(s)(G1); or R 1 is a C 3 -C 28 moiety which comprises at least one cyclic structure and which may be saturated or unsaturated and which may optionally be interrupted and/or substituted by one or more hetero atom(s) (Het1) and functional group(s)(G1); R 2 is H; or R 2 is a Mono-phosphate, Di-phosphate, Tri-phosphate or phosphoramidite moiety; or R 2 is -Y-X or -Y-L-Y 1 - X; Y and Y 1 are independently from each other a single bond or a functional connecting moiety, X is a colloid-active compound (CA) or a fluorescence marker (FA) or a polynucleotide moiety having up to 50 nucleotide residues, preferably 10 to 25 nucleotides, especially a polynucleotide having an antisense or antigen effect; L is a linker by means of which Y and X are covalently linked together; R 3 and R 4 represent independently from each other a C 1 -C 28 -alkyl moiety which may optionally be substituted or interrupted by one or more heteroatom(s) and/or functional group(s);or R 3 and R 4 form a ring having at least 5 members, preferably a ring having 5 to 8 carbon atoms and wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s); or R 3 and R 4 represent independently from each other a C 1 -C 28 -alkyl moiety substituted with one or more moieties selected from the group -Y-X or -Y-L-Y 1 -X; or R 3 and R 4 represent independently from each other -Y-X or -Y-L-Y 1 - X; R 5 and R 6 represent independently from each other a C 1 -C 28 -alkyl moiety which may optionally be substituted or interrupted by one or more heteroatom(s) and/or functional group(s); or R 5 and R 6 represent independently from each other a C 1 -C 28 -alkyl moiety substituted with one or more moieties selected from the group -Y-X or -Y-L-Y 1 -X; or R 5 and R 6 form a ring having at least 5 members, preferably a ring having 5 to 18 carbon atoms and wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s); and/or one or more moieties selected from the group -Y-X or -Y-L-Y 1 - X; R 5 and R 6 represent independently from each other -Y-X or -Y-L-Y 1 - X; R 7 is a hydrogen atom or -O-R 8 ; R 8 is H or C 1 -C 28 chain which may be branched or linear and which may be saturated or unsaturated and which may optionally be interrupted and/or substituted by one or more hetero atom(s) (Het1) and/or functional group(s)(G1); or R 8 is -Y-X or -Y-L-Y 1 - X, with the proviso that R 1 and R 2 are not both H and/or with the proviso that the compound comprises at least two chains each of which having 4 or more carbon atoms.